For instance, in a retrospective analysis of 1007 patients undergoing PET/CT with a radiolabeled small molecule PSMA-ligand (i.e. 68Ga-PSMA-11) for the evaluation of recurrent prostate cancer, the detection rate in patients with PSA levels ≤1 ng/ml was reported to be 57% (Afshar-Oromieh et al., 2017). The gene discussed is FOLH1; the disease is prostate carcinoma.